Advanced search
1 file | 691.65 KB

Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils

Author
Organization
Abstract
INTRODUCTION: Asthma with adult onset and elevated blood eosinophils is a difficult-to-treat subgroup. This post hoc analysis evaluated reslizumab, an anti-interleukin-5 monoclonal antibody, in patients with late-onset eosinophilic asthma. METHODS: Data from two 52-week placebo-controlled trials of reslizumab IV 3 mg/kg every 4 weeks in patients aged 12-75 years with inadequately controlled asthma, ≥1 asthma exacerbation within 12 months, and screening blood eosinophils ≥400/μL (NCT01287039/NCT01285323) were stratified by age of asthma onset (<40 or ≥40 years). Annual clinical asthma exacerbation rates, change in lung function, and patient-reported outcomes were analyzed. RESULTS: 273 patients with late-onset asthma (placebo, n = 130; reslizumab, n = 143) and 658 with early-onset asthma (placebo, n = 336; reslizumab, n = 322) were included. Baseline demographics were similar between groups. The interaction between age at onset of asthma and effect of reslizumab on asthma exacerbations was statistically significant (p = 0.0083). Compared with placebo, reslizumab produced a 75% relative reduction in asthma exacerbations in patients with late-onset asthma (rate ratio [RR] 0.25; 95% confidence interval [CI], 0.16, 0.40), substantially larger than the reduction in earlier onset patients (RR 0.58; 95% CI, 0.44, 0.76). Similar findings were observed for other measures of asthma, including forced expiratory volume in 1 s (FEV1). The adverse event profile of reslizumab was similar in patients with early- or late-onset asthma. CONCLUSIONS: Compared with placebo, reslizumab produced larger reductions in asthma exacerbations and larger improvements in lung function in patients with late versus early-onset asthma.
Keywords
Asthma, Late onset, Reslizumab

Downloads

  • Brusselle Reslizumab in patients.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 691.65 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Brusselle, Guy, Matthew Germinaro, Sivan Weiss, and James Zangrilli. 2017. “Reslizumab in Patients with Inadequately Controlled Late-onset Asthma and Elevated Blood Eosinophils.” Pulmonary Pharmacology & Therapeutics 43: 39–45.
APA
Brusselle, G., Germinaro, M., Weiss, S., & Zangrilli, J. (2017). Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. PULMONARY PHARMACOLOGY & THERAPEUTICS, 43, 39–45.
Vancouver
1.
Brusselle G, Germinaro M, Weiss S, Zangrilli J. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. PULMONARY PHARMACOLOGY & THERAPEUTICS. 2017;43:39–45.
MLA
Brusselle, Guy, Matthew Germinaro, Sivan Weiss, et al. “Reslizumab in Patients with Inadequately Controlled Late-onset Asthma and Elevated Blood Eosinophils.” PULMONARY PHARMACOLOGY & THERAPEUTICS 43 (2017): 39–45. Print.
@article{8515332,
  abstract     = {INTRODUCTION: Asthma with adult onset and elevated blood eosinophils is a difficult-to-treat subgroup. This post hoc analysis evaluated reslizumab, an anti-interleukin-5 monoclonal antibody, in patients with late-onset eosinophilic asthma.
METHODS: Data from two 52-week placebo-controlled trials of reslizumab IV 3 mg/kg every 4 weeks in patients aged 12-75 years with inadequately controlled asthma, \ensuremath{\geq}1 asthma exacerbation within 12 months, and screening blood eosinophils \ensuremath{\geq}400/\ensuremath{\mu}L (NCT01287039/NCT01285323) were stratified by age of asthma onset ({\textlangle}40 or \ensuremath{\geq}40 years). Annual clinical asthma exacerbation rates, change in lung function, and patient-reported outcomes were analyzed.
RESULTS: 273 patients with late-onset asthma (placebo, n = 130; reslizumab, n = 143) and 658 with early-onset asthma (placebo, n = 336; reslizumab, n = 322) were included. Baseline demographics were similar between groups. The interaction between age at onset of asthma and effect of reslizumab on asthma exacerbations was statistically significant (p = 0.0083). Compared with placebo, reslizumab produced a 75\% relative reduction in asthma exacerbations in patients with late-onset asthma (rate ratio [RR] 0.25; 95\% confidence interval [CI], 0.16, 0.40), substantially larger than the reduction in earlier onset patients (RR 0.58; 95\% CI, 0.44, 0.76). Similar findings were observed for other measures of asthma, including forced expiratory volume in 1 s (FEV1). The adverse event profile of reslizumab was similar in patients with early- or late-onset asthma.
CONCLUSIONS: Compared with placebo, reslizumab produced larger reductions in asthma exacerbations and larger improvements in lung function in patients with late versus early-onset asthma.},
  author       = {Brusselle, Guy and Germinaro, Matthew and Weiss, Sivan and Zangrilli, James},
  issn         = {1094-5539},
  journal      = {PULMONARY PHARMACOLOGY \& THERAPEUTICS},
  keyword      = {Asthma,Late onset,Reslizumab},
  language     = {eng},
  pages        = {39--45},
  title        = {Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils},
  url          = {http://dx.doi.org/10.1016/j.pupt.2017.01.011},
  volume       = {43},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: